Dear Editor,The coronavirus disease 2019(COVID-19),caused by the Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2),is an ongoing threat to public health.Due to the presence of neutralizing antibodies in conv...Dear Editor,The coronavirus disease 2019(COVID-19),caused by the Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2),is an ongoing threat to public health.Due to the presence of neutralizing antibodies in convalescent patients,convalescent plasma transfusion has been tested as a promising therapy for severe COVID-19 patients.12 We and others previously found a surprisingly early serum lgA antibody response in the COVID-19 patients.However,the relative contribution of the lgA antibody towards virus neutralization with respect to other antibody isotypes is unknown.展开更多
基金This work was supported by grants from the Strategic Priority Research Program of the Chinese Academy of Sciences(XDB29030104)National Natural Science Fund(31870731,31971129 and U1732109)the Fundamental Research Funds for the Central Universities,the new medical science fund of USTC,COVID-19 special task grants supported by Chinese Academy of Science Clinical Research Hospital(Hefei)with Grant Nos.YD2070002017 and YD2070002001,respectively.
文摘Dear Editor,The coronavirus disease 2019(COVID-19),caused by the Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2),is an ongoing threat to public health.Due to the presence of neutralizing antibodies in convalescent patients,convalescent plasma transfusion has been tested as a promising therapy for severe COVID-19 patients.12 We and others previously found a surprisingly early serum lgA antibody response in the COVID-19 patients.However,the relative contribution of the lgA antibody towards virus neutralization with respect to other antibody isotypes is unknown.
